Kairos Pharma, LTD. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Kairos Pharma, LTD. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($1.40M) | Nov 14, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($1.42M) | Aug 12, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($1.26M) | May 14, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($1.05M) | Nov 14, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($253.0K) | Aug 12, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($323.0K) | May 14, 2025 |
| Q3 | 2024 | Dec 31, 2023 | $1.81M | Nov 14, 2024 |
| Q3 | 2024 | Sep 30, 2023 | ($312.0K) | Nov 14, 2024 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($1.44M) | Nov 14, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($1.46M) | Aug 12, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($1.27M) | May 14, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($383.0K) | Nov 14, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($222.0K) | Aug 12, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($287.0K) | May 14, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($287.0K) | Nov 14, 2024 |